Frederic Bouder is Assistant Professor at Maastricht University in the Department of Technology and Society Studies and Research Associate at King's College London. For over ten years he has developed policy oriented research on risk communication and risk regulation. Frederic has focused on a range of pharmaceutical issues including cardiovascular conditions, impurities in drugs, antivirals, vaccines, biotechnologies and genetic testing.

Esther de Vries is a pharmacovigilance assessor at the Dutch national agency (MEB), while finishing her PhD at the University Medical Center Groningen in the Netherlands. Her PhD centres around the Direct Healthcare Professional Communication (DHPC) in the hospital setting in the Netherlands. In addition to these activities, she is involved in digitalising the DHPC in the Netherlands.

Randip Kahlon is the Global Risk Management Therapeutic Area Lead for Oncology at Bristol Myers Squibb, with 20 years experience in pharmacovigilance and risk management. He has co-authored scientific publications on risk minimisation effectiveness evaluation studies and presented on digital approaches for risk minimisation at several external conferences. Randip holds a BSc (Hons) Degree in Medical Biochemistry and Diploma in Professional Development, both from Brunel University London.

Ryan has over 10 years’ experience in the field of patient safety and medicines development, in both CRO and big pharma environments, encompassing clinical and post-marketing products across a broad range of therapeutic areas. Most recently, Ryan has specialised in risk management implementation, successfully leading and coordinating complex global risk management strategies including digital elements to plan.

Bianca Mulder is a pharmacist with a PhD in pharmacoepidemiology. Her research focused on the use of medication during pregnancy and the development of atopic diseases in children. She worked briefly in a pharmacovigilance position at a pharmaceutical company before she started working as a pharmacovigilance assessor at the Dutch national agency (MEB) in 2016.

Maarten Lagendijk is the deputy QPPV at MSD since 2019 and is based in the Netherlands. Maarten has over 20 years of experience in pharmacovigilance. He has previously worked for the Medicines Evaluation Board in different pharmacovigilance related roles as well as a national expert at the European Medicines Agency.  Maarten has been involved with DIA for many years and is part of the programme committee for the Global QPPV Forum since 2020. 

James has extensive experience in pharmacovigilance and patient safety, with his most recent role on the Patient Safety Operations Leadership Team at AstraZeneca as Senior Director Device and Digital safety. In the past, James has been a Life Science Consultant, a Safety Scientist performing safety risk/signal management and a case processor. James holds a BSc in Psychology and an MSc and MBA with a focus on Patient Safety. In addition, he contributed actively to industry-wide initiatives through DIA and Transcelerate.